Last reviewed 2026-05-24 · How we verify

Shuxinin injection

Peking University Third Hospital · FDA-approved active Small molecule Under review

Shuxinin injection is a Traditional Chinese medicine injection Small molecule drug developed by Peking University Third Hospital. It is currently FDA-approved for Angina pectoris, Cerebral infarction, Peripheral vascular disease.

Shuxinin is a traditional Chinese medicine injection that promotes blood circulation and removes blood stasis to alleviate pain and improve microcirculation.

Shuxinin injection is being studied in a clinical trial for the treatment of acute ischemic stroke. The exact mechanism of Shuxinin injection is currently unknown.

At a glance

Generic name	Shuxinin injection
Sponsor	Peking University Third Hospital
Drug class	Traditional Chinese medicine injection
Modality	Small molecule
Therapeutic area	Pain management, Cardiovascular
Phase	FDA-approved

Mechanism of action

Shuxinin is derived from traditional Chinese medicine principles and is formulated to invigorate blood flow and eliminate stagnation. It is used clinically to improve tissue perfusion, reduce inflammation, and alleviate pain associated with poor circulation and microvascular dysfunction. The exact molecular targets and mechanisms have not been fully characterized in Western pharmacological terms.

Approved indications

Angina pectoris
Cerebral infarction
Peripheral vascular disease
Pain relief associated with blood stasis

Common side effects

Local injection site reactions
Allergic reactions
Gastrointestinal upset

Key clinical trials

Study on the Effectiveness and Safety of Shuxinin Injection in the Treatment of Acute Ischemic Stroke (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Shuxinin injection CI brief — competitive landscape report
Shuxinin injection updates RSS · CI watch RSS
Peking University Third Hospital portfolio CI

Frequently asked questions about Shuxinin injection

What is Shuxinin injection?

Shuxinin injection is a Traditional Chinese medicine injection drug developed by Peking University Third Hospital, indicated for Angina pectoris, Cerebral infarction, Peripheral vascular disease.

How does Shuxinin injection work?

Shuxinin is a traditional Chinese medicine injection that promotes blood circulation and removes blood stasis to alleviate pain and improve microcirculation.

What is Shuxinin injection used for?

Shuxinin injection is indicated for Angina pectoris, Cerebral infarction, Peripheral vascular disease, Pain relief associated with blood stasis.

Who makes Shuxinin injection?

Shuxinin injection is developed and marketed by Peking University Third Hospital (see full Peking University Third Hospital pipeline at /company/peking-university-third-hospital).

What drug class is Shuxinin injection in?

Shuxinin injection belongs to the Traditional Chinese medicine injection class. See all Traditional Chinese medicine injection drugs at /class/traditional-chinese-medicine-injection.

What development phase is Shuxinin injection in?

Shuxinin injection is FDA-approved (marketed).

What are the side effects of Shuxinin injection?

Common side effects of Shuxinin injection include Local injection site reactions, Allergic reactions, Gastrointestinal upset.

Drug class: All Traditional Chinese medicine injection drugs
Manufacturer: Peking University Third Hospital — full pipeline
Therapeutic area: All drugs in Pain management, Cardiovascular
Indication: Drugs for Angina pectoris
Indication: Drugs for Cerebral infarction
Indication: Drugs for Peripheral vascular disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing